Liquid biopsy approaches to capture minimal residual disease and therapy response in patients with early stage cancers is a research paper published in International review of cell and molecular biology (2024). On theSindex it has a DataRank of 0.
Scored on demand from live citation data
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: CA121113
AstraZeneca
Grant: 17/779,936
AstraZeneca
Grant: 16/312,152
AstraZeneca
Grant: 63/276,525
AstraZeneca
Grant: 17/598,690
AstraZeneca
Grant: 16/341,862
AstraZeneca
Grant: 17/047,006
NCI NIH HHS
Grant: R01 CA121113
NCI NIH HHS
Grant: UG1 CA233259
MeSH Terms
Keywords